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HDQToxoplasma gondii does not possess complex I of the mitochondrial respiratory
chain, but has two genes encoding rotenone-insensitive, non-proton pumping type-II NADH dehydrogenases
(NDH2s). The absence of such “alternative” NADH dehydrogenases in the human host deﬁnes these enzymes
as potential drug targets. TgNDH2-I and TgNDH2-II are constitutively expressed in tachyzoites and
bradyzoites and are localized to the mitochondrion as shown by epitope tagging. Functional expression of
TgNDH2-I in the yeast Yarrowia lipolytica as an internal enzyme, with the active site facing the mitochondrial
matrix, permitted growth in the presence of the complex I inhibitor DQA. Bisubstrate kinetics of TgNDH2-I
measured within Y. lipolytica mitochondrial membrane preparations were in accordance with a ping-pong
mechanism. Using inhibition kinetics we demonstrate here that 1-hydroxy-2-alkyl-4(1)quinolones with long
alkyl chains of C12 (HDQ) and C14 are high afﬁnity inhibitors for TgNDH2-I, while compounds with shorter
side chains (C5 and C6) displayed signiﬁcantly higher IC50 values. The efﬁciency of the various quinolone
derivatives to inhibit TgNDH2-I enzyme activity mirrors their inhibitory potency in vivo, suggesting that a
long acyl site chain is critical for the inhibitory potential of these compounds.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
NADH:ubiquinone oxidoreductases, also known as NADH dehy-
drogenases constitute one of the electron entry points into the
respiratory chain, oxidizing NADH and generating ubiquinol. In
eukaryotes, this class of enzymes is divided into two major
subfamilies, which can be discriminated on the basis of cofactor
content and sensitivity towards rotenone into type-I NADH dehy-
drogenases (complex I) and type-II NADH dehydrogenases (NDH2s)
[1]. Proton-pumping complex I is a nearly ubiquitous enzyme that
couples the rotenone-sensitive transfer of electrons from NADH to
ubiquinone with the active transport of protons across the inner
mitochondrial membrane [2]. Bacterial complex I typically consists of
fourteen subunits that are homologous to the seven mitochondrially
coded and the seven nuclear coded “central” subunits of the
eukaryotic enzyme. Although eukaryotic complex I contains a variable
number of so-called accessory subunits, with a total of 45 subunits and, 1-Hydroxy-2-Dodecyl-4(1H)
; HPQ, 1-Hydroxy-2-Pentyl-4
nolone
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l rights reserved.a molecular mass of roughly 1 MDa in mammals, the bioenergetic
function and the overall structure are conserved [3,4].
In contrast to complex I, type-II NADH dehydrogenases are non-
proton-pumping, rotenone-insensitive, single polypeptides. Their
active site can face either to the cytosol (external enzymes), thereby
oxidizing cytosolic NADH, or to the mitochondrial matrix (internal
enzymes), thereby oxidizing mitochondrial NADH. Seven NDH2
isoforms are expressed in Arabidopsis, three of them are identiﬁed
as internal enzymes, whereas the other four are external [5]. In Sac-
charomyces cerevisiae mitochondria lacking complex I, one internal
and two external enzymes have been described [6].
Type-II NADH dehydrogenases have been described in plants,
fungi, protozoa and bacteria [1,7], but appear to be absent in
mammals, which qualiﬁes them as attractive drug targets. The
apicomplexan parasites Plasmodium falciparum and Toxoplasma gondii,
which are the causative agents of malaria and toxoplasmosis
respectively, both lack complex I. Instead, the genome of P. falci-
parum is predicted to encode a single NDH2 of unknown orientation,
while the T. gondii genome encodes two NDH2 isoforms. Treatment of
P. falciparum with micromolar concentrations of diphenylene iodo-
nium chloride, a low afﬁnity inhibitor of NDH2, resulted in an
inhibition of PfNDH2 activity, in a collapse of the parasite's
mitochondrial membrane potential and ﬁnally in parasite death [8].
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(HDQ)was described as the ﬁrst high afﬁnity inhibitor of type-II NADH
dehydrogenases that inhibits NDH2 activity in mitochondrial mem-
branes of the yeast Yarrowia lipolyticawith an IC50 of 200 nM [9]. We
have recently shown that HDQ is highly effective against T. gondii and
inhibits parasite replication with an IC50 in the nanomolar range [10].
Moreover, a combined treatment of HDQ with the complex III
inhibitor atovaquone resulted in synergism [10].
To further elucidate the suitability of type-II NADH dehydro-
genases as drug targets it is crucial to obtain functional data from
pathogen orthologs and to determine their interaction with
putative inhibitors. We here report functional expression of
TgNDH2-I in the yeast Y. lipolytica. This allowed us to study the
kinetics of this enzyme and to demonstrate that 1-hydroxy-2-alkyl-
4(1)quinolones with long alkyl side chains are high afﬁnity
inhibitors for TgNDH2-I.
2. Materials and methods
2.1. Genome data mining and sequence analyses
Preliminary genomic and/or cDNA sequence data were accessed via
http://ToxoDB.org (version 3.0) [11] and/or http://tigr.org/tdb/t_gondii/.
Genomic datawere provided by the Institute for Genomic Research (NIH
grant #AI05093), and by the Sanger Center (Wellcome Trust). EST
sequences were generated by Washington University (NIH grant
#1R01AI045806-01A1). Bioinformatics programs including MitoProt II
3.0 (http://ihg.gsf.de/ihg/mitoprot.html) andSignalIP3.0 (http://ww.cgs.
dtu.dk/services/SignalIP/) were used to predict subcellular location of
Tgndh-I and Tgndh2-II.
2.2. Determination of the ATG initiation codons
An in-frame stop codon is present at 783 and 51 nt upstream of
the presumed initiation ATG codons of tgndh2-I and tgndh2-II
respectively. The deduced amino acid sequences coded by these
regions have no other in-frame methionine residues and no similarity
to NDHs nor to other proteins when blasted using NCBI BLAST. For
tgndh2-I the next methionine residue is located 177 nt downstream
of the ﬁrst one. However, only the amino acid sequence deduced
from the ﬁrst ATG has characteristics of a mitochondrial targeting
sequence. For tgndh2-II, a putative second start ATG is located 6 nt
downstream of the ﬁrst.
2.3. RNA extraction, RT-PCR and fusion-PCR
Total RNA was isolated using the GenElute Mammalian Total RNA
Kit (Sigma) and treated with DNase I (Sigma). Reverse transcription
(RT) was done on 5 μg of total RNA, Oligo(dT) primer (Sigma) and M-
MLV reverse transcriptase (RNase H minus, Sigma) according to the
manufacturer's instructions. For PCR ampliﬁcation, the reaction
mixture was cycled in a thermal cycler. Fusion-PCR ampliﬁcation
was ﬁrstly performed in a volume of 50 μl containing 50 ng of each
puriﬁed DNA fragment (QIAquick PCR puriﬁcation kit, Qiagen) with 5
cycles of PCR in the absence of primers. The PCR reaction was
continued for another 7 cycles after adding the primer sets (BamHI-
NUAM-Fusion+ with NDH2-I-FL− or NDH2-II-FL−).
2.4. Real-time PCR
Light cycler PCR (Roche) was performed to amplify cDNA of
tgndh2-I, tgndh2-II and β-tubulin with the following primer sets RT-
AND1/1+ and 2−, RT-AND2/1+ and 2−, and RT-Tub/3+ and 4−, as listed
in Supplementary Table 1. A control sample without reverse
transcriptase was incubated in parallel. The threshold crossing-point
values of tgndh2-I and tgndh2-II were normalized to that of β-tubulin.2.5. Immunoﬂuorescence microscopy
Samples were ﬁxed with 4% paraformaldehyde/PBS for 10 min and
permeabilized with 0.25% Triton X-100/PBS for 15 min. After blocking
for 1 hwith 1% BSA/PBS, samples were incubatedwith a 1:250 dilution
of anti-myc mAb 9E10 (Sigma) followed by incubation with a 1:500
dilution of Cy3-conjugated anti-mouse IgG (Dianova) in 1% BSA/PBS
for 1 h each.
2.6. T. gondii strains, cultivation and in vitro stage conversion
Parasites were propagated in human foreskin ﬁbroblasts (HFF) as
previously described [12]. A clonal isolate of the RH strainwas used for
in vitro stage conversion and preparation of cDNA for real time RT-PCR
analysis. Transactivator expressing T. gondii of strain RH TATi-1 [13]
were kindly provided by Dr. D. Soldati and Dr. M. Meissner and used
for transfection experiments. Bradyzoites obtained by in vitro stage
conversion were prepared as follows. T. gondii infected HFFs were
ﬁrstly cultivated in 1% FCS/DMEM for 3 h at 37 °C in a 5% CO2
humidiﬁed atmosphere. The mediumwas subsequently replaced with
pH-shift medium (pH 8.3) to induce bradyzoite differentiation [14]
and the cultures were incubated at 37 °C without CO2. The medium
was changed daily with fresh pH-shift medium to remove the
extracellular parasites and maintain a constant culture pH. After 4-
day incubation, cells were detached and harvested for RNA isolation.
2.7. Generation of myc-tagged Tgndh2-I and Tgndh2-II for expression in
parasites
The complete open reading frames (ORF) of Tgndh2-I and Tgndh2-II
were ampliﬁed from cDNA of the RH strain using Pfu polymerase
(Promega) with the primer sets AND1/ORF1+_AﬂII and AND1/ORF2−_
AvrII, and AND2/ORF1+_NsiI and AND2/ORF2_AvrII, respectively. The
PCR fragments were cloned into pCR4.0-TOPO (Invitrogen) and DNA
sequenced. The AﬂII/AvrII and NsiI/AvrII fragments were ﬁnally
subcloned into pTetO7Sag4-acyl carrier protein (ACP)-cmyc-DHFR
vector (kindly provided by Dr. B. Striepen), thereby replacing the ACP
ORF with the Tgndh2-I and Tgndh2-II ORFs. The ﬁnal constructs
pTetSag4-ndh2-I-cmyc-DHFR and pTet7Sag4-ndh2-II-cmyc-DHFR
consisted of the anhydrotetracycline (Atc)-regulable TetO7Sag4
promoter element [15], which controls the expression of the complete
Tgndh2-I and Tgndh2-II ORFs with a C-terminal myc-tag, and
additionally includes a pyrimethamine resistance cassette for selec-
tion [16]. Parasites (2×107) were electroporated with 50 μg of NotI-
linearized constructs as previously described [12]. Not I (25 U) was
added to the cytomix before electroporation in order to increase the
frequency of stable transfectants [17]. Stably transfected parasites
were selected with 1 μM pyrimethamine.
2.8. Plasmid construction and Y. lipolytica transformation
The NUAM-Tgndh2s fusion constructs were generated as transla-
tional fusions comprising the Y. lipolytica mitochondrial targeting
sequence of the complex I NUAM subunit [18] and the corresponding
Tgndh2-I or Tgndh2-II mature peptides. The NUAM DNA fragments
were ampliﬁed by PCR from plasmid pUB38 [19] using proof-reading
Phusion DNA polymerase (Finnzymes' Phusion high-ﬁdelity DNA
polymerase, NEB) with sense primer BamHI-NUAM-Fusion+ and the
corresponding antisense primers YL-NDH2-I-24−, YL-NDH2-I-51− and
YL-NDH2-II-62− (Supplementary Table S1). For obtaining DNA frag-
ments for the mature parts of the Tgndh2-I-(AA24), Tgndh2-I-(AA51)
and Tgndh2-II-(AA62) constructs, cDNA isolated from the RH strain
was used as a template for PCR ampliﬁcation with the following
primer sets: YL-NDH2-I-24+ and NDH2-I-FL−, YL-NDH2-I-51+ and
NDH2-I-FL, and YL-NDH2-II-62+ and NDH2-II-FL−, respectively. The
NUAM-Tgndh2 fusions were achieved by fusion-PCR. To create the
Fig. 2. Real-time PCR analysis for TgNDH2-I and TgNDH2-II mRNA transcripts. HFFswere
infected with RH strain tachyzoites in alkaline medium of pH 8.3 to induce bradyzoite
differentiation. Total RNAwas isolated from tachyzoites at 24 h post-infection and from
bradyzoites at 4 days post-infection. Light cycler PCR was performed to amplify cDNAs
of TgNDH2-I and TgNDH2-II. β-tubulin was used as an internal control. Values are
represented in terms of x-fold increase in the mRNA transcripts of TgNDH2-I and
TgNDH2-II in tachyzoites compared to that in bradyzoites after normalization to
β-tubulin mRNA transcripts. Results are expressed as mean±S.D. of the duplicate wells
of two independent experiments.
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FL− for Tgndh2-I, and NDH2-II-FL+ and NDH2-II-FL− for Tgndh2-II
were used as shown in Supplementary Table S1. All PCR fragments
were cloned into pDrive vector (PCR cloning kit, Qiagen) according to
the manufacture's protocol, and then subcloned into the BamHI and
EcoRI sites of the Y. lipolytica/E. coli shuttle vector pUB30 [19],
behind the pPOX2 promoter. All clones were sequenced and
conﬁrmed with correct orientation. Y. lipolytica haploid NDH2
deletion strain GB5.2 [20] was used for transformation with pUB30
constructs encoding TgNDH2-I and TgNDH2-II full-length, or NUAM-
TgNDH2-I and NUAM-TgNDH2-II fusion constructs. Transformants
were grown in rich glucose medium in the presence of 100 µg/ml
Hygromycin B.
2.9. Preparation of mitochondrial membranes
Mitochondrial membranes were isolated as previously described
[9]. In brief, cells were harvested and resuspended in ice-cold buffer
containing 600 mM sucrose, 20 mM Na+/Mops, pH 7.4, 1 mM EDTA,
and 2 mM phenyl-methylsulfonyl ﬂuoride, and disrupted by glass
beads. Mitochondrial membranes were collected from the super-
natant and further homogenized, shock-frozen and stored at −80 °C.
Samples were aliquoted for kinetic measurements and protein
determination.
2.10. Kinetic measurements
NADH:DBQ oxidoreductase activity of mitochondrial membranes
from Y. lipolytica expressing Tgndh2-I and Tgndh2-II was measured at
30 °C in a reaction mixture containing 20 mM Na+/Mops (pH 7.4),
50 mM NaCl, 2 mM KCN, 0.1 μM NADH, 60 μM DBQ, and 100 μg/ml
mitochondrialmembranes in the presence of 27 μMcomplex I inhibitor
DQA. The reaction was initiated by adding DBQ and monitored using a
plate reader spectrophotometer (SPECTRAmax PLUS 384, Molecular
Devices). Enzyme activities were recorded in terms of velocity (v,
unit: μM Umin−1 Umg−1). The applied DBQ concentrations were in the
range from 2.5–100 µM (at 100 µM NADH) and the NADH concentra-
tions were in the range from 10–100 µM (at 60 µM DBQ). Data were
analysed according to the equations detailed in [9]. Determination ofFig. 1. Mitochondrial localization of myc-tagged TgNDH2-I and TgNDH2-II in parasites. RH
cmyc-DHFR), harboring the complete ORFs of TgNDH2-I and TgNDH2-II. The myc-tagged fus
For co-localization experiments, stably transfected parasites expressing the ectopic TgND
mitochondrially targeted GFP fusion.Michaelis–Menten parameters was by direct ﬁt using the ENZFITTER
software package (Biosoft, Cambridge). HDQ and HDQ analogues were
kindly provided by Dr. W. Oettmeier and were dissolved in tissue
culture grade DMSO (Sigma).
2.11. Nucleotide sequence accession numbers of Tgndh2-I and Tgndh2-II
genes
Sequence data of Tgndh2-I and Tgndh2-II were submitted to
GenBank with accession numbers DQ211932 and DQ228957,
respectively.
3. Results
3.1. T. gondii expresses two mitochondrial NDH2 isoforms but no
complex I
Based on BLAST homology searches, the genome of T. gondii is
predicted to encode conventional respiratory chain components, with
the exception of the multi-subunit, proton-translocating NADHstrain tachyzoites were transfected with expression plasmids (pTetO7Sag4-NDH2-I/II-
ion proteins were detected by immunoﬂuorescence staining using anti-myc mAB 9E10.
H2-I and TgNDH2-II genes were co-transfected with pCAT S9-GFP, which encodes a
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and TGG_994290) with high similarities to type-II NADH dehydro-
genases were identiﬁed in the ToxoDB. The complete open reading
frames of both genes were ampliﬁed, subcloned and sequenced from T.
gondii RH strain cDNA. The two genes encoding the type-II NADH
dehydrogenases were designated as tgndh2-I (accession#: DQ211932)
and tgndh2-II (accession#: DQ228957). They encode precursor polypep-
tides of 619 and 657 amino acids with predicted masses of 67.1 and
72.1 kDa, respectively. Information on gene structures is given in
Supplementary Fig. S1. The deduced primary structure of both proteins
includes N-terminal mitochondrial targeting sequences as predicted byFig. 3. TgNDH2-I displaysNADH:DBQ oxidoreductase activity. (A) Schematic diagram depicting
position for the mature parts of TgNDH2-I and TgNDH2-II. AA, amino acid; FL, full-length.
mitochondrialmembranes from Y. lipolytica strain GB5.2 containing pUB30-TgNDH2-I, TgNDH2
the complex I inhibitor DQA. Student's t-test; ⁎pb0.0001; ⁎⁎pb0.001; ⁎⁎⁎pb0.02 versus contro
dilutions including 1, 10, 100 and 1000 cells/ml were plated on complete media in the absencMitoProt II and SignalP 3.0. To verify the mitochondrial localization of
TgNDH2-I and TgNDH2-II, we performed epitope tagging experiments.
The complete open reading frames (ORF) of bothgeneswere fused to aC-
terminally located c-myc epitope and the resulting expression plasmids
(pTetO7Sag4-NDH2-I/II-cmyc-DHFR) were introduced into RH strain
parasites of the TATi-1 line by electroporation. Immunoﬂuorescence
analysis of stably transfected parasite populations revealed that both
isoforms were targeted to the single T. gondii mitochondrion as
conﬁrmed by co-localization with the mitochondrial marker S9-GFP
[21] that had been co-transfected into NDH2-myc expressing parasites
(Fig. 1). We examined tgndh2-I and tgndh2-II transcript levels in the twothe constructs established for Y. lipolytica transformation. The arrows indicate the coding
(B) Oxidoreductase activity was measured in a reaction mixture containing 100 μg/ml
-II or control pUB30 vector,100 µMNADHand60 µMDBQas substrates in the presence of
l pUB30 vector. (C) TgNDH2-I confers resistance to the complex I inhibitor DQA. A series of
e or presence 5 μM DQA.
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human host by quantitative real time RT-PCR. Both genes displayed
comparable mRNA levels in the analyzed stages (Fig. 2), suggesting that
they were constitutively expressed rather than stage speciﬁcally
regulated.
3.2. Functional expression of TgNDH2-I in Y. lipolytica
The yeast Y. lipolytica expresses a single, external, non-essential
NDH2 and has been established as a model organism for studying the
biochemistry of alternative NADH dehydrogenases [22] and of
respiratory chain complex I [23]. We used Y. lipolytica strain GB 5.2,
in which the external NDH2 was deleted, for heterologous expression
of TgNDH2-I and TgNDH2-II. It is not knownwhether a mitochondrial
import sequence from a T. gondii protein is sufﬁcient for accurate
targeting into Y. lipolytica mitochondria. Thus, in addition to full-
length T. gondii constructs, we also employed fusions of the N-
terminal part of the Y. lipolytica mitochondrial NUAM protein and
mature versions of TgNDH2-I and TgNDH2-II. The predicted start
position for mature TgNDH2-I is at amino acid 24 and for mature
TgNDH2-II at amino acid 62 (Fig. 3A). The predicted presequence for
TgNDH2-I is relatively short and after a manual sequence alignment
with TgNDH2-II, a second, although less likely start position for
mature TgNDH2-I was identiﬁed at position 51 and used for NUAM
fusion. It has been demonstrated previously that the addition of the
NUAM mitochondrial import signal to the external Y. lipolytica NDH2
is sufﬁcient to convert this enzyme into an internal, enzymatically
active isoform [18]. All constructs were placed under the control of the
pPOX2 promotor in the replicative vector pUB30 [19]. Mitochondrial
membrane preparations of Y. lipolytica transformants were analyzedFig. 4. Inhibition of TgNDH2-I by HDQ derivatives differing in side chain length. The concent
mitochondrial membranes was determined at a total protein concentration of 100 µg/ml in t
side chains, respectively.for NADH dehydrogenase activity in an enzymatic assay using DBQ as
electron acceptor. The NUAM-TgNDH2-I fusions displayed electron
transfer activities that were 10-fold (construct A: AA24) and 5-fold
(construct B: AA51) higher than controls, demonstrating that this
isoform can be expressed as an active enzyme in Y. lipolytica (Fig. 3B).
Both TgNDH2-II constructs displayed electron transfer activities that
were less than 2-fold above controls, and the activity of full-length
TgNDH2-I was less than 2.5-fold above controls.
Complex I, the proton-translocating multi-subunit NADH dehy-
drogenase of the mitochondrial respiratory chain, is essential for
growth of Y. lipolytica. The ability of the ﬁve expression constructs to
compensate for the loss of complex I activity was tested in a Y. lipo-
lytica growth assay on YPD agar plates in the presence of the complex I
inhibitor DQA. Expression of TgNDH2-I as NUAM fusion proteins
conferred DQA resistance (Fig. 3C), in line with the results obtained
from the enzyme activity assay. This demonstrated that both NUAM-
TgNDH2-I fusions were expressed as functional, internal enzymes
with their active site oriented towards the mitochondrial matrix.
NUAM-TgNDH2-I expressed from construct A which displayed the
highest activity and was used in all kinetic assays and is termed
TgNDH2i in the following.
3.3. TgNDH2i activity is effectively inhibited by 1-hydroxy-2-alkyl-4(1H)
quinolones
The quinolone-like compound HDQ is a potent inhibitor of Y. lipoly-
tica NDH2 [9] and our recent ﬁndings have shown that HDQ could
effectively inhibit T. gondii replication [10]. We thus investigated the
inhibitory effect of HDQ on the NADH dehydrogenase activity of
TgNDH2i in unsealed Y. lipolytica mitochondrial membranes. Usingration of inhibitor required for half-maximal inhibition (IC50) of TgNDH2i in Y. lipolytica
he presence of 60 µM DBQ and 100 µM NADH. (A–D) HDQ with C12, C14, C5 and C6 alkyl
Fig. 6. Double reciprocal plots of HDQ inhibition kinetics of TgNDH2i. Inhibition kinetics
of TgNDH2i in Y. lipolytica mitochondrial membranes were measured at a total protein
concentration of 100 µg/ml for A, DBQ (at 100 µM NADH) and B, NADH (at 60 µM DBQ)
in the absence (♦) and in the presence of 60 nM (□) and 300 nM (▴) C12-HDQ. The lines
for the diagrams were calculated using parameters obtained from direct ﬁts to the
Michaelis–Menten equation. In A, Vmax values were 0.92±0.06 (♦), 0.76±0.03 (□) and
0.41±0.02 (▴) units/mg. Apparent Km values for DBQ were 13.8±2.4 (♦), 13.8±2.0 (□)
and 12.9±2.5 µM (▴). In B, Vmax values were 1.16±0.07 (♦), 0.80±0.04 (□) and 0.44±
0.03 (▴) U/mg. Apparent Km values for NADH were 76±7 (♦), 68±5 (□) and 61±8 µM
(▴). Each data point represents the mean of ﬁve independent measurements.
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activity by HDQ was dose dependent with a concentration required for
half-maximal inhibition (IC50) of about 300 nM (Fig. 4A). A 1-hydroxy-
2-alkyl-4(1H)quinolone compound with a C14 alkyl side chain (HTQ,
Fig. 4B) displayed a similar IC50 as HDQ (C12), while derivates with
shorter alkyl side chains (C5=HPQ and C6=HHQ) were less effective
with signiﬁcantly higher IC50 values of about 3700 nM and 2300 nM,
respectively (Fig. 4C, D).
3.4. TgNDH2i bisubstrate kinetics suggest a ping-pong reaction
mechanism
Mitochondrial membrane preparations from Y. lipolytica expres-
sing TgNDH2i were used to determine bisubstrate kinetics for NADH
and DBQ. Km values of 76 µM for NADH and 14 µM for DBQ were
obtained. In a Hanes plot ([S]/v over [S]) of the kinetic data, the
obtained lines crossed close to the y-axis (Fig. 5), which is in
accordance with a ping-pong reaction mechanism for TgNDH2i [9].
A (random or ordered) sequential mechanism could be excluded since
in that case the lines would cross in the fourth quadrant. This result
suggests that the enzyme forms binary complexes with each of the
substrates, but is unable to form a ternary complex with both
substrates. Most likely, both substrates interact with a common
binding site in a mutually exclusive fashion.
3.5. HDQ inhibition follows a non-competitive pattern for both substrates
To determine the mode of inhibition of HDQ on TgNDH2i in
mitochondrialmembranepreparations from Y. lipolytica, we performed
steady-state inhibition kinetics for both NADH and DBQ. Double
reciprocal plots of the kinetic data obtained in the presence of 0, 60
and 300 nM HDQ are depicted in Fig. 6. With increasing HDQ
concentrations, the slopes increased, and the lines intersected close
to the y-axis. Similar as found with Y. lipolytica NDH2 [9], these results
formally follow the pattern of non-competitive inhibition for both
substrates and similar values for the two inhibition constants (seeFig. 5. TgNDH2-I employs a ping-pong reaction mechanism. Hanes plots of steady-state
kinetics with TgNDH2i in Y. lipolytica mitochondrial membranes, assayed at a total
protein concentration of 100 µg/ml. Vmax and apparent Km values for DBQ in the
presence of ﬁve different NADH concentrations were obtained from direct ﬁts to the
Michaelis–Menten equation and used to draw the lines. NADH concentrations were 10
(□), 15 (♦), 30 (▵), 50 (▪) and 100 µM (w). Vmax values were 0.17±0.01 (□), 0.28±0.04
(♦), 0.40±0.04 (▵), 0.57±0.06 (▪) and 0.77±0.07 (w) U/mg. Apparent Km values were
3.5±0.5 (□), 5.3±2.9 (♦), 9.1±2.8 (▵),11.9±4.1 (▪) and 18.0±5.0 µM (w). Each data point
represents the mean of ﬁve independent measurements.Supplementary Fig. S2). Using linear secondary plots of the slopes and
y-axis intercepts of the lines in Fig. 6 against the HDQ concentrations
used, numeric values for the inhibition constants could be derived from
the points of intersection with the x-axis (see Supplementary Fig. S3).
Secondary plots of the slopes thus gave Ki=283 nM and Kii=292 nM,
and secondary plots of the intercepts gave Ki=234 nM and Kii=198 nM.
Within experimental error, these results are in excellent agreement
with the directly determined IC50 value for HDQ on TgNDH2i and with
the assumption that Ki equals Kii.
4. Discussion
In this study we have determined enzymatic parameters from
heterologously expressed, functionally active T. gondii NDH2-I and
could show that 1-hydroxy-2-alkyl-4(1)quinolones with long alkyl
chains are high afﬁnity inhibitors for this enzyme. T. gondii lacks
complex I but possesses two mitochondrial type-II NADH dehydro-
genases. Both are constitutively expressed, hampering direct deter-
mination of individual enzymatic parameters in T. gondii lysates. Thus,
for in vitro characterization, we have expressed TgNDH2-I in a strain of
the yeast Y. lipolytica that lacks endogenous alternative NADH
dehydrogenase activity. Functional expression of TgNDH2-I as an
internal NADH dehydrogenase, capable of electron transfer from
matrix NADH to membrane bound ubiquinone, was achieved by
fusing the TgNDH2-I open reading frame without the endogenous
mitochondrial targeting sequence to the N-terminal part of the NUAM
subunit of Y. lipolyticamitochondrial complex I. Direct evidence for in
vivo function of TgNDH2i was provided by the observation that
expression of the transgene allowed cells of Y. lipolytica to survive in
1461S.S. Lin et al. / Biochimica et Biophysica Acta 1777 (2008) 1455–1462the presence of the complex I inhibitor DQA. Thus we were able to
achieve heterologous expression of a protozoan type-II NADH
dehydrogenase in an active form. Functional expression of protozoan
type-II NADH dehydrogenases in Y. lipolytica should facilitate future
comparative studies of apicomplexan orthologs. In addition, expres-
sion of protozoan type-II enzymes in Y. lipolytica could be used for the
development of a screening assay to identify novel, speciﬁc inhibitors
for this class of enzymes.
The steady-state inhibition kinetics of TgNDH2-I for the quinolone
derivative HDQ were found to be very similar to those of Y. lipolytica
NDH2 [9] and formally follow the pattern of non-competitive
inhibition for both substrates, NADH and DBQ. In the case of a ping-
pong reaction mechanism, this inhibition pattern is predicted when
the inhibitor blocks both the enzyme, here TgNDH2i-FAD and the
intermediate form, here TgNDH2i-FADH2 [24]. As with Y. lipolytica
NDH2 [9], our data thus support a model in which the inhibitor can
interact with a complex consisting of the enzyme and one of its
substrates, presumably NADH, as depicted in Supplementary Fig. S2.
Bisubstrate kinetics revealed that the NADH:DBQ oxidoreductase
activity of TgNDH2i followed a ping-pong reaction mechanism, a mode
of action that was also shown for the Y. lipolytica ortholog [9] and
proposed for the S. cerevisiae and T. brucei enzymes [25,26]. The
determined Km (NADH) of 76 µMwas signiﬁcantly higher than the Km of
most other eukaryotic enzymes, for example from S. tuberosum, N.
crassa and S. cerevisiae, which were in the range of 11–32 µM [7]. Only
the T. brucei enzyme with 120 µM displayed a higher Km than the T.
gondii ortholog [26]. Also, the Km (DBQ) of 14 µM observed for TgNDH2i
was higher than the Km (DBQ) of 7.0 µM for Y. lipolytica NDH2 [9].
However, differences in Km values have to be interpreted with caution,
since different electron acceptorswere used in these studies and speciﬁc
reaction conditions as the volume of the lipid phase could inﬂuence
activities. Since the activity of TgNDH2i was about 4-fold lower than the
activity of NDH2, the external alternative NADH dehydrogenase of Y.
lipolytica parental strains, we had to double the amount of total
mitochondrial protein used in the assays. Lower effective concentrations
of DBQ in the lipid phase would explain the elevated Km (DBQ) values
observed in the present study. In contrast, the Km (NADH) is not
expected to depend on the volume of the lipid phase.
The IC50 value of about 300 nMobtained for HDQ indicates that this
compound is a high afﬁnity inhibitor for TgNDH2-I. The only other
NDH2 enzyme for which the IC50 value for HDQ is known is the Yar-
rowia orthologue, which with 200 nM is in the same range [9]. In the
future, it will be important to determine IC50 values for further
orthologues from pathogenic and non-pathogenic microorganisms, in
order to classify HDQ as a broad spectrum NDH2 inhibitor or as an
inhibitor with a selected inhibitory potential. An example for a
respiratory chain inhibitor with a selected inhibitory potential is the
clinically approved antimalaria drug atovaquone. This drug is a
complex III inhibitor that interferes with the ubiquinol oxidation site
of the cytochrome bc1 complex by acting as a competitive inhibitor for
ubiquinol. Atovaquone possesses antimicrobial activity against certain
apicomplexan parasites such as Plasmodium and Toxoplasma and the
opportunistic fungal pathogen Pneumocystis carinii, whereas the
human and bovine cytochrome bc1 complexes are insensitive towards
atovaquone [27].
For HDQ, the in vitro IC50 of ~300 nM for inhibition of TgNDH2i
activity is signiﬁcantly higher than the in vivo IC50 of 2–4 nM for static
effects on T. gondii parasites, determined in tissue culture after a 24 h
treatment period [10]. Apparent differences in IC50 values should not
be overinterpreted since these are strongly dependent on the
fractional volume of the lipid phase. Assuming that a highly
hydrophobic substance like HDQ will partition to the hydrophobic
phase, the effective HDQ concentration for interaction with type-II
NADH dehydrogenase may well differ by two orders of magnitude
between the two assay systems. However, we can not exclude at
present that HDQ inhibits other ubiquinone dependent NADHoxidoreductases such as succinate dehydrogenase, dihydroorotate
dehydrogenase, glycerol-3-phosphate dehydrogenase and the malate:
quinone oxidoreductase, in addition to type-II NADH dehydrogenases.
A long alkyl side chain of C12 or C14 at position 2 is critical for the
inhibition of NADH:DBQ oxidoreductase activity. Compounds with
short alkyl side chains of C5 (HPQ) and C6 (HHQ) with 3700 nM and
2300 nM displayed signiﬁcantly higher IC50 values as compoundswith
long alkyl side chains of C12 (HDQ, IC50=300 nM) and C14 (HTQ,
IC50=300 nM). On the basis of structural similarities, it is tempting to
speculate that 1-hydroxy-2-alkyl-4(1H)quinolones are likely to
compete with ubiquinone for the same binding site. A long alkyl site
chain leads to a higher hydrophobicity and is likely to render the
physicochemical properties and the structure of 1-hydroxy-2-alkyl-4
(1H)quinolones more similar to ubiquinone. Another aspect is the
partition of the compounds between aqueous and membrane lipid
phase. Highly hydrophobic 1-hydroxy-2-alkyl-4(1H)quinolones as
HDQ and HTQ, in contrast to those with smaller alkyl side chains,
can be expected to partition almost quantitatively into the membrane
lipid phase. The correlation between IC50 values and length of the
alkyl side chain mirrored the in vivo-efﬁciency of these drugs to
inhibit parasite replication: HPQ (C5) did not show any inhibitory
effect at 10 nM, while parasite growth was reduced to more than 50%
by HDQ and HTQ at this concentration [10]. A reevaluation of the
efﬁciency of HHQ (C6) to inhibit T. gondii replication yielded an IC50 of
220 nM for HHQ (C6), which is more than 50-fold higher than the IC50
for HDQ (data not shown). Together, these data reveal that only 1-
hydroxy-2-alkyl-4(1H)quinolones with long alkyl site chains are
effective TgNDH2-I inhibitors and antiparasitic drugs.
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